Immix Biopharma (IMMX) financial statements
Net income was -$29M.
Free cash flow was -$25M.
The diluted share count rose 877% over the period (dilution).
Income statement
Fiscal years, from Immix Biopharma's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $248,149 | $126,527 | $4M | $9M | $11M | $16M |
| Selling, general and admin | $205,703 | $1M | $4M | $7M | $11M | $14M |
| Operating income | -$453,852 | -$1M | -$8M | -$16M | -$23M | -$30M |
| Interest expense | $101,976 | $179,853 | $497 | — | — | — |
| Pre-tax income | -$1M | -$24M | -$8M | -$16M | -$22M | -$29M |
| Income tax | $17,547 | $6,013 | $10,268 | $26,415 | $41,037 | $37,724 |
| Net income | -$1M | -$24M | -$8M | -$15M | -$22M | -$29M |
| EPS (diluted) | -$0.34 | -$6.64 | -$0.59 | -$0.89 | -$0.76 | -$0.89 |
| Diluted shares | 3M | 4M | 14M | 17M | 28M | 33M |
Balance sheet
Fiscal years, from Immix Biopharma's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $391,086 | $18M | $13M | $18M | $18M | $100M |
| Total current assets | $532,236 | $18M | $15M | $20M | $20M | $101M |
| Property, plant and equipment | $7,361 | $5,695 | $3,560 | $50,181 | $2M | $3M |
| Total assets | $539,597 | $18M | $15M | $20M | $23M | $105M |
| Total current liabilities | $5M | $202,039 | $1M | $4M | $9M | $10M |
| Total liabilities | $5M | $202,039 | $2M | $4M | $10M | $11M |
| Shareholders' equity | -$5M | $18M | $13M | $16M | $13M | $94M |
| Net debt | -$391,086 | -$18M | -$13M | -$18M | -$18M | -$94M |
Cash flow
Fiscal years, from Immix Biopharma's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$404,694 | -$2M | -$7M | -$11M | -$15M | -$24M |
| Capital spending | — | $802 | — | $52,089 | $1M | $732,925 |
| Free cash flow | — | -$2M | — | -$11M | -$16M | -$25M |
| Stock-based compensation | — | $218,983 | $624,069 | $3M | $3M | $2M |
| Share buybacks (net) | — | — | -$99,963 | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMMX.
Open IMMX in InvestinglyQuestions
How much free cash flow does Immix Biopharma generate?
-$25M in fiscal 2025 (operating cash flow minus capital spending).
From Immix Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.